Charts NXS, page-353

Hi Stickshift.

...so chipping away at the trade shows is the best way forward for BlastX to be used most appropriately because that is the only way into the hospitals?


Although the fact its primary effectiveness is in surgical situations need not preclude incorporating it into regular household products ?

Again my thinking is perhaps too simplistic, but I had thought to compete with the Dettols and iodines, it simply needs to be an effective antibacterial able to match the price of competitors, with a point of difference to give it a marketing edge over them.

I am not averse to the slow road, I just felt there might be other opportunities to broaden awareness and drive uptake.

...3M has exclusive global partnerships rights to BlastX for three years (either from November 2018 when the deal was signed or from January 2019 when the NXS team handed over ) so perhaps the theorising is a bit pointless .

Thank you for your perspective which sounds knowledgeable : )
Cheers